Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05914519
Other study ID # Soh-Med-23-06-02MD
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date January 1, 2025

Study information

Verified date June 2023
Source Sohag University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the outcomes and efficacy of ejaculatory preserving TURP in terms of voiding, erectile function, and ejaculation.


Description:

The prostatic gland plays a central role in andrology. It is involved both in fertility and in sexuality with a major role in ejaculation and possibly in orgasm. This could explain the association between the andrological symptoms and prostatic disorders. The prevalence of Benign Prostatic Hyperplasia (BPH) is approximately 50% for men in their fifties and reaches up to 80% for men over 80 years of age, representing one of the most common diseases affecting males, with potentially significant impact on their quality of life. It is estimated that around half of men suffering severe or medical treatment unresponsive lower urinary tract symptoms (LUTS) will be offered a surgical procedure to relieve benign prostatic obstruction (BPO). Despite continuing development of new minimally invasive surgical methods, transurethral resection of the prostate (TURP) still remains the gold standard surgical treatment for LUTS due to BPH. Although it is benign, this disease has been shown to have a negative impact on the patient's health-related quality of life (HRQL), marked by obstructive and irritative LUTS. As BPH in most cases is not a life-threatening condition, the main outcomes of its treatment are not only the improvement in LUTS and functional parameters but also quality of life after surgery. Whilst efficacy of the conventional TURP is proven, a common potentially bothersome side effect, the retrograde ejaculation (RE) which occurs in 65-90% of patients undergoing TURP. It has been reported that ablative techniques like TURP and recent laser procedures including holmium, thulium and greenlight cause similar rates of ejaculatory dysfunction, occurring in almost three out of four to five men. For decades, men have been counseled to expect dry orgasm after TURP because of the retrograde flow of semen as a result of bladder neck disruption. Erectile dysfunction and Ejaculatory dysfunction (EjD) can have a substantial deleterious effect on the Quality of life (QoL) of men who have previously maintained regular sexual activity, inducing significantly increased levels of anxiety and depression. More recently, a better understanding of ejaculation physiology has enabled the emergence of modified surgical techniques with the aim of preserving antegrade ejaculation. The key point of standard TURP is resecting the tissues enveloped in the prostatic capsule and the bladder neck, while protecting the urethral tissues below the verumontanum. The bladder neck plays a significant role in reproduction. For men, bladder neck closure facilitates anterograde ejaculation. It actively contracts the bladder neck during ejaculation through a rich noradrenergic innervation by sympathetic nerves. Vernet et al. showed that contraction of the bladder neck was not important for anterograde ejaculation. Using endorectal ultrasound videos performed during masturbation in 30 men, it was possible to visualize the bladder neck, the prostate, and the bulbar urethra during ejaculation. They observed that during ejaculation, the verumontanum underwent a slight caudal shift, momentarily making contact with the opposite urethral wall and sperm emitted from the ejaculatory ducts was directed distally by contractions of the external sphincter coordinated with contractions of the bulbar urethra, thus demonstrating the importance of the muscular tissue around the verumontanum and particularly its proximal part. They described this area as a "high-pressure ejaculatory area". The closure of the bladder neck did not seem to play a role in this mechanism. As a result, one can conclude that as long as the tissues around the verumontanum are not injured, ejaculation should still occur even with a well-open bladder neck. Recently, together with a better understanding of the mechanisms of ejaculation, a greater importance has been given to the impact of dry ejaculation on patients' QoL. A balance between symptomatic improvement in LUTS and preservation of sexual function needs to be addressed for men seeking surgical treatment. Modifications based on Supramontanal sparing hypothesis have reported favorable outcomes to as high as 92%. Although preservation of bladder neck structures is often associated with preservation of antegrade ejaculation, the current modern approach is the preservation of the precollicular and para-collicular tissue in the area where the ejaculatory ducts emerge near the verumontanum in the distal apical tissue in laser, aquablation, and bipolar electrosurgical prostatectomy techniques.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date January 1, 2025
Est. primary completion date November 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 45 Years and older
Eligibility Inclusion Criteria: - Adult patient > 45 years old. - Drug refractory urinary retention. - Prostate volume range: 20-60 mL. - IPSS > 19 after the medical therapy failure. - Qmax < 10 mL/s. - PSA < 4 ng/mL. - Active and healthy sexual life. Exclusion Criteria: - History of prostate or urethral surgery. - Neurogenic bladder. - UTI. - Urethral stricture disease. - prostate cancer. - Bleeding diathesis. - Capsular or bladder perforation during surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ejaculatory Preserving Transurethral resection of prostate
Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
Standard Transurethral Resection of prostate
Transurethral resection of prostate including whole adenoma till the capsule.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Outcome

Type Measure Description Time frame Safety issue
Primary International Prostate Symptom Score IPSS assess voiding which has a range from 0 to 35. Increase in score means worsening of symptoms 6 months
Primary Uro-flow-metry (Qmax) Qmax assess voiding. Decrease in Qmax means worsening of voiding. Unit of Qmax is ml/sec 6 months
Primary Male Sexual Health Questionnaire - Ejaculatory Dysfunction short form (MSHQ-EjD) MSHQ-EjD assess ejaculation. It consist of 2 items, the first is ejaculatory function which ranges from 1 to 15 and increase in score means improving of ejaculation. The second is satisfaction score which ranges from 0 to 5 and increase in score means worsening of ejaculation. 6 monthes
Primary International Index of erectile function IIEF score assess erection. It ranges from 5 to 25. Increase in score means improving of erectile function. 6 months
Secondary Complication Rate of complications will be assessed 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02974751 - Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Terminated NCT04398966 - Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia N/A
Completed NCT04029012 - Penthrox in Rezūm BPH Phase 4
Recruiting NCT03912558 - Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients. N/A
Completed NCT00527488 - Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Phase 2
Recruiting NCT06323109 - US Imaging for the Assessment of LUTS
Completed NCT05628025 - Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
Completed NCT00407329 - Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia N/A
Completed NCT00256399 - Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) N/A
Terminated NCT03994263 - A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI N/A
Completed NCT03772808 - Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS) N/A
Completed NCT05818670 - Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study Phase 4
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Active, not recruiting NCT04198103 - Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia N/A
Completed NCT00696761 - The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Phase 4
Completed NCT00199550 - Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Phase 4
Completed NCT02702947 - Efficacy of Prunus Domestica Extract in BPH Phase 4
Completed NCT00154843 - A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Phase 2
Completed NCT00037141 - Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Phase 1/Phase 2
Recruiting NCT05620784 - Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP Phase 3